Daniel E. Furst

Developing a Standardized Definition for Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group)

Mahboob Rahman, M. Boers, D. Furst, 2009, The Journal of Rheumatology.

Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?

D. Furst, K. Brune, Daniel E. Furst, 2007, Rheumatology.

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

G. Herrero-Beaumont, P. Tak, M. Genovese, 2004, Annals of the rheumatic diseases.

Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritis

D. Furst, C. Booth-LaForce, M. McGann, 2010, Annals of the rheumatic diseases.

AB0244 Development of an adjusted multi-biomarker disease activity (MBDA) score for rheumatoid arthritis (RA) that accounts for age, sex and adiposity, with subsequent evaluation of ability to predict risk for radiographic damage

A. Gutin, M. Weinblatt, N. Shadick, 2018, Rheumatoid arthritis – prognosis, predictors and outcome.